A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix.
The purpose of this study was to evaluate the efficacy and the toxicity of mitomycin, ifosfamide, and cisplatin in patients with recurrent carcinoma of the cervix. Between July 1992 and March 1995, 20 patients with recurrent cervical cancer were enrolled in this study. No patients had received prior chemotherapy for metastatic disease, except some were exposed to cisplatin as a radiosensitizer at the time of their diagnosis. Mitomycin-C 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2 were given intravenously every 3 weeks. All patients were assessible for response and toxicity, and none was lost to follow-up. All patients except one had squamous cell carcinoma. The overall response rate was 45% (2 complete remissions and 7 partial remissions). The mean response duration was 35 months, and the median survival from treatment for the whole group was 14 months. Fifteen percent of all cycles produced grade 3 or 4 myelosuppression, and the main nonhematologic toxicity was nausea and vomiting, which was reported in 11.5% of all cycles. One death occurred secondary to chemotherapy-induced septicemia. Three patients are still alive, two with a complete response and one with a partial response. In conclusion, mitomycin, ifosfamide, and cisplatin have a good activity in recurrent carcinoma of the cervix and are comparable to other combination chemotherapy.
Division of Medical Oncology, Division of Gynecology-Oncology, Department of Radiation Oncology, McGill Comprehensive Cancer Centre, Montreal, Quebec, Canada; and Bristol-Myers Squibb, Montreal, Quebec, Canada.
M.
M
Trudeau
R.
R
Seymour
G.
G
Stanimir
L.
L
Souhami
L.
L
Arthur
H.
H
Dulude
G.
G
Gallant
B.
B
Leyland-Jones